骨粗鬆症治療薬と骨折治療薬市場：薬剤、投与経路、流通別-2025-2030年の世界予測

骨粗鬆症治療薬と骨折治療薬市場の2023年の市場規模は138億米ドルで、2024年には149億7,000万米ドルに達すると予測され、CAGR 8.53％で成長し、2030年には244億8,000万米ドルに達すると予測されています。

抗骨粗鬆症療法と骨折治療市場は、特に骨が弱くなる骨粗鬆症の患者を対象に、骨密度の低下を防ぎ骨折からの回復を改善する治療に焦点を当てています。この市場を牽引しているのは、高齢化人口の増加、骨粗鬆症とそれに伴う骨折の有病率の増加、医薬品治療と医療機器の進歩です。これらの治療法は、骨折に関連するヘルスケアコストを削減し、患者の生活の質を向上させるために不可欠です。その用途は病院、整形外科クリニック、在宅医療に及び、ビスフォスフォネート製剤、ホルモン補充療法、骨折治癒に使用される生体材料の成長などの治療を提供しています。主な成長要因としては、技術の進歩、骨の健康に対する意識の高まり、低侵襲治療へのシフトなどが挙げられます。最新のビジネスチャンスは個別化医療と生物製剤にあり、骨の健康に関与する遺伝的要因と細胞メカニズムに関する継続的な研究がその原動力となっています。企業は、戦略的パートナーシップ、研究開発投資を通じて、こうした動向を活用することができます。しかし市場は、治療費の高騰、治療による副作用の可能性、規制当局の厳しい承認、代替療法やサプリメントとの競合といった課題に直面しています。技術革新が必要な分野としては、新規ドラッグデリバリーシステムの開発、組織工学、幹細胞や成長因子に注目した再生医療技術などが挙げられます。さらに、骨粗鬆症の早期発見のための診断ツールの改良は、大きな事業成長の可能性をもたらします。市場は非常にダイナミックで、集中的な研究開発と進化する規制状況によって特徴付けられ、企業は機敏さと適応力を維持する必要があります。費用対効果が高く、安全で効率的なソリューションを生み出すと同時に、消費者教育の格差に対処する積極的な戦略は、このような環境で成功するために極めて重要です。利害関係者は、医療提供者や政策立案者との関係を育み、患者のアクセスを促進し、治療計画における十分な情報に基づいた意思決定をサポートする必要があります。

市場力学：急速に進化する骨粗鬆症治療薬と骨折治療薬市場の主要市場インサイトを公開

骨粗鬆症治療薬と骨折治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の老人人口の増加
  • 急速な都市化とライフスタイルの変化による骨疾患の増加
  • 女性における閉経後骨粗鬆症の増加
• 市場抑制要因
  • 抗骨粗鬆症薬と骨折治療薬の高コスト
• 市場機会
  • 新薬導入のための研究開発の成長
  • 骨粗鬆症に対する意識の高まりと健康への影響
• 市場の課題
  • 抗骨粗鬆症薬と骨折治癒に関連する合併症と副作用

ポーターのファイブフォース：骨粗鬆症治療薬と骨折治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：骨粗鬆症治療薬と骨折治療薬市場における外部からの影響の把握

外部マクロ環境要因は、骨粗鬆症治療薬と骨折治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析骨粗鬆症治療薬と骨折治療薬市場における競合情勢の把握

骨粗鬆症治療薬と骨折治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス骨粗鬆症治療薬と骨折治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、骨粗鬆症治療薬と骨折治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨骨粗鬆症治療薬と骨折治療薬市場における成功への道筋を描く

骨粗鬆症治療薬と骨折治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で高齢化が進む
    • 急速な都市化とライフスタイルの変化により、

骨疾患の発生

• 女性の閉経後骨粗鬆症の発症率が増加
• 抑制要因
  • 骨粗鬆症治療薬と骨折治療薬の高額な費用
• 機会
  • 新薬イントロダクションおける研究開発の拡大
  • 骨粗鬆症とその健康への影響についての継続的な認識
• 課題
  • 骨粗鬆症治療薬と骨折治癒に関連する合併症と副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 骨粗鬆症治療薬と骨折治療薬市場薬物別

• アレンドロネート
• バイオホスホネート
• イバンドロネート
• リセドロネート
• 選択的エストロゲン受容体モジュレーター
  • ラロキシフェン
  • ストロンチウムラネレテ
• ゾレドロン酸

第7章 骨粗鬆症治療薬と骨折治療薬市場：投与経路別

• 注射可能
• オーラル

第8章 骨粗鬆症治療薬と骨折治療薬市場配布元

• ドラッグストア
• eコマース市場
• 病院
• 個人クリニック
• 小売薬局

第9章 南北アメリカの骨粗鬆症治療薬と骨折治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の骨粗鬆症治療薬と骨折治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの骨粗鬆症治療薬と骨折治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amgen Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Healthy Life Pharma Pvt. Ltd.
• Johnson & Johnson Services, Inc.
• Manus Aktteva Biopharma LLP
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Salvavidas Pharmaceutical Private Limited
• Sanofi S.A.
• Taj Pharmaceuticals
• Taj Pharmaceuticals Limited
• Teva Pharmaceuticals Industries Ltd

LIST OF FIGURES

• FIGURE 1. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET RESEARCH PROCESS
• FIGURE 2. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET DYNAMICS
• TABLE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BIOPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STRONTIUM RANELETE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY E-COMMERCE MARKET, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 39. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 40. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 41. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 61. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 62. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 63. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 65. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 66. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 67. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 134. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 135. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 136. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 150. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 151. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 152. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 154. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 155. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 156. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 157. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 194. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 195. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, 2023

The Anti-Osteoporosis Therapy & Fracture Healing Market was valued at USD 13.80 billion in 2023, expected to reach USD 14.97 billion in 2024, and is projected to grow at a CAGR of 8.53%, to USD 24.48 billion by 2030.

The anti-osteoporosis therapy and fracture healing market focuses on treatments that prevent bone density loss and improve recovery from bone fractures, especially for individuals with osteoporosis, a condition that weakens bones. This market is driven by a rising aging population, increased prevalence of osteoporosis and associated fractures, and advancements in pharmaceutical therapies and medical devices. These therapies are essential for reducing healthcare costs associated with fractures and improving the quality of life for patients. Their application spans hospitals, orthopedic clinics, and home healthcare, offering treatments like bisphosphonates, hormone replacement therapies, and growth in biomaterials used in fracture healing. Key growth influences include technological advancements, increased awareness about bone health, and a shift towards minimally invasive treatments. Latest opportunities lie in personalized medicine and biologics, driven by ongoing research on genetic factors and cellular mechanisms involved in bone health. Companies can capitalize on these trends through strategic partnerships, research, and development investment. However, the market faces challenges, such as high treatment costs, potential side effects of therapies, stringent regulatory approvals, and competition from alternative therapies and supplements. Areas ripe for innovation include the development of novel drug delivery systems, tissue engineering, and regenerative medicine techniques focusing on stem cells and growth factors. Additionally, improving diagnostic tools for early osteoporosis detection can offer substantial business growth potential. The market is highly dynamic, characterized by intensive R&D and evolving regulatory landscapes, requiring companies to remain agile and adaptive. Proactive strategies producing cost-effective, safe, and efficient solutions while addressing consumer education gaps are crucial for thriving in this environment. Stakeholders need to foster relationships with healthcare providers and policymakers to facilitate patient access and support informed decision-making in treatment planning.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Osteoporosis Therapy & Fracture Healing Market

The Anti-Osteoporosis Therapy & Fracture Healing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising geriatric population worldwide
  • Rapid urbanization coupled with changing lifestyle is increasing the occurrence of bone diseases
  • Growing incidences of postmenopausal osteoporosis in women
• Market Restraints
  • High cost of the anti-osteoporosis medications & fracture healing treatments
• Market Opportunities
  • Growing research and development in introduction of new drugs
  • Ongoing awareness of osteoporosis and its impact on health
• Market Challenges
  • Complication and side effects related to with anti-osteoporosis medications & fracture healing

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Osteoporosis Therapy & Fracture Healing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Osteoporosis Therapy & Fracture Healing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Osteoporosis Therapy & Fracture Healing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Osteoporosis Therapy & Fracture Healing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Osteoporosis Therapy & Fracture Healing Market

A detailed market share analysis in the Anti-Osteoporosis Therapy & Fracture Healing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Osteoporosis Therapy & Fracture Healing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Osteoporosis Therapy & Fracture Healing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Osteoporosis Therapy & Fracture Healing Market

A strategic analysis of the Anti-Osteoporosis Therapy & Fracture Healing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Osteoporosis Therapy & Fracture Healing Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Healthy Life Pharma Pvt. Ltd., Johnson & Johnson Services, Inc., Manus Aktteva Biopharma LLP, Merck & Co., Inc., Novartis AG, Pfizer Inc., Salvavidas Pharmaceutical Private Limited, Sanofi S.A., Taj Pharmaceuticals, Taj Pharmaceuticals Limited, and Teva Pharmaceuticals Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Anti-Osteoporosis Therapy & Fracture Healing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug, market is studied across Alendronate, Biophosphonates, Ibandronate, Risedronate, Selective Oestrogen Receptor Modulators, and Zoledronic Acid. The Selective Oestrogen Receptor Modulators is further studied across Raloxifene and Strontium Ranelete.
• Based on Route Of Administration, market is studied across Injectable and Oral.
• Based on Distribution, market is studied across Drug Stores, E-Commerce Market, Hospitals, Private Clinics, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising geriatric population worldwide
    • 5.1.1.2. Rapid urbanization coupled with changing lifestyle is increasing the

occurrence of bone diseases

• 5.1.1.3. Growing incidences of postmenopausal osteoporosis in women
• 5.1.2. Restraints
  • 5.1.2.1. High cost of the anti-osteoporosis medications & fracture healing treatments
• 5.1.3. Opportunities
  • 5.1.3.1. Growing research and development in introduction of new drugs
  • 5.1.3.2. Ongoing awareness of osteoporosis and its impact on health
• 5.1.4. Challenges
  • 5.1.4.1. Complication and side effects related to with anti-osteoporosis medications & fracture healing
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anti-Osteoporosis Therapy & Fracture Healing Market, by Drug

• 6.1. Introduction
• 6.2. Alendronate
• 6.3. Biophosphonates
• 6.4. Ibandronate
• 6.5. Risedronate
• 6.6. Selective Oestrogen Receptor Modulators
  • 6.6.1. Raloxifene
  • 6.6.2. Strontium Ranelete
• 6.7. Zoledronic Acid

7. Anti-Osteoporosis Therapy & Fracture Healing Market, by Route Of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral

8. Anti-Osteoporosis Therapy & Fracture Healing Market, by Distribution

• 8.1. Introduction
• 8.2. Drug Stores
• 8.3. E-Commerce Market
• 8.4. Hospitals
• 8.5. Private Clinics
• 8.6. Retail Pharmacies

9. Americas Anti-Osteoporosis Therapy & Fracture Healing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Anti-Osteoporosis Therapy & Fracture Healing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Anti-Osteoporosis Therapy & Fracture Healing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. Eli Lilly and Company
• 3. F. Hoffmann-La Roche Ltd.
• 4. GlaxoSmithKline plc
• 5. Healthy Life Pharma Pvt. Ltd.
• 6. Johnson & Johnson Services, Inc.
• 7. Manus Aktteva Biopharma LLP
• 8. Merck & Co., Inc.
• 9. Novartis AG
• 10. Pfizer Inc.
• 11. Salvavidas Pharmaceutical Private Limited
• 12. Sanofi S.A.
• 13. Taj Pharmaceuticals
• 14. Taj Pharmaceuticals Limited
• 15. Teva Pharmaceuticals Industries Ltd